Research Milestones for Cystic Fibrosis

Timeline created by christina1989
  • First Comprehensive Medical report written about CF

    First Comprehensive Medical report written about CF
    Dorothy Andersen, M.D. writes the first comprehensive medical report on cystic fibrosis (CF).
  • CF Research goes National

    CF Research goes National
    The Cystic Fibrosis Foundation becomes incorporated as the National CF Research Foundation and awards the first research grants to Drs. di Sant’Agnese, Andersen and Shwachman.
  • Predicted survival age is 10 years old

    Predicted survival age is 10 years old
    The CF foundation predicts median survival age is 10 years old.
  • 30 CF Care Centers Open

    30 CF Care Centers Open
    A total of 30 Cystic Fibrosis Foundation-accredited care centers are now in operation.
  • More than 100 CF Care Centers open

    More than 100 CF Care Centers open
    The number of Cystic Fibrosis Foundation-accredited care centers totals more than 100.
  • Research Program is created

    Research Program is created
    The Cystic Fibrosis Foundation creates the Research Development Program, a network of research centers at leading universities and medical schools nationwide.
  • First CF Pharmacy

    First CF Pharmacy
    The Cystic Fibrosis Foundation launches the Cystic Fibrosis Services Pharmacy
  • A defective gene is found.

    A defective gene is found.
    A team of Cystic Fibrosis Foundation-supportes scientists discovers the defective CF gene and its protein product (CFTR) thus opening the door to understanding the disease at its most basic level.
  • Gene Therapy trials begin

    Gene Therapy trials begin
    Landmark gene therapy trial begins in people with CF.
  • FDA approves Pulmozyme

    FDA approves Pulmozyme
    The Food and Drug Administration (FDA) approves Pulmozyme, which is proven to thin the tenacious, sticky mucus in the lungs - and is the first drug developed specifically for CF. The time taken to develop Pulmozyme is less than half of the industry average.
  • First Therapeutic Program

    First Therapeutic Program
    The Cystic Fibrosis Foundation establishes the Therapeutics Development Program.
  • First antibiotic created.

    First antibiotic created.
    The FDA approves TOBI, the first aerosolized antibiotic designed for CF, which is proven to reduce hospital stays and improve lung function
  • Various drug discoveries.

    Various drug discoveries.
    Cystic Fibrosis Foundation Therapeutics, nonprofit research affiliate of the CF Foundation was established to govern drug discovery and development efforts.
  • Genetic structure created

    Genetic structure created
    Scientists supported by the Cystic Fibrosis Foundation map the entire genetic structure of the most common cause of CF lung infections-the Pseudomonas aeruginosa bacterium. Researchers can identify the function of specific genes and find ways (drugs) to turn off the bad ones.
  • Supported studies in Austria

    Supported studies in Austria
    Cystic Fibrosis Foundation Therapeutics-supported studies in Australia and at the University of North Carolina show that hypertonic saline helps clear CF mucus. It is proven to improve lung function and reduce hospital stays, and becomes a therapeutic option.
  • X-770 enters clinical trial

    X-770 enters clinical trial
    X-770, a drug in development by Vertex Pharmaceuticals with support from the Cystic Fibrosis Foundation, enters clinical trials. VX-770 is one of the first compounds to attack the root cause of CF, and works at the cellular level to open chloride channels that do not function correctly in people with the disease.
  • Survival age increases to 37.

    Survival age increases to 37.
    The predicted median age of survival for those with CF increases to 37 years.
  • FDA approves antibiotic

    FDA approves antibiotic
    Gilead Sciences, Inc. applies for FDA approval for its inhaled antibiotic therapy, aztreonam lysine, which has been shown to improve respiratory symptoms in CF patients.
  • Second potential drug created.

    Second potential drug created.
    Vertex Pharmaceuticals selects a second potential drug known as VX-809 for development. Like VX-770, VX-809 addresses the root cause of CF, but it works by helping the defective CF protein move to its proper place in the cell.
  • Proof of achievement

    Proof of achievement
    The Foundation and Vertex Pharmaceuticals achieve a “proof of concept,” showing that it is possible to treat the root cause of CF. During Phase 2 studies of VX-770, trial participants, all of whom carry the G551D mutation of CF, show unprecedented improvements in key signs of the disease.
  • All New Borns scanned for CF

    All New Borns scanned for CF
    All 50 states and the District of Columbia now require newborns to be screened for CF.
  • New drug shows results.

    New drug shows results.
    VX-809, a second Vertex drug aimed at treating the basic CF defect, shows encouraging results in a Phase 2a clinical trial.More than 30 potential therapies are in the Foundation’s drug discovery and development pipeline. The more drugs in the pipeline, the greater the odds of producing successful therapies and a cure for CF.
  • Period: to

    Milestones in Research